Linked Life Data

20955343

Source:http://linkedlifedata.com/resource/pubmed/id/20955343

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20955343rdf:typepubmed:Citationlld:pubmed
pubmed-article:20955343lifeskim:mentionsumls-concept:C1416433lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C1564138lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C0917725lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:20955343lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:20955343pubmed:issue6lld:pubmed
pubmed-article:20955343pubmed:dateCreated2010-12-24lld:pubmed
pubmed-article:20955343pubmed:abstractTextEngineered skin substitutes (ESSs) comprising both keratinocytes and fibroblasts can afford many advantages over the use of autologous keratinocyte grafts for the treatment of full-thickness and partial-thickness burns. In this study, we investigated the efficacy of a novel ESS containing both genetically altered fibroblasts that express the immunosuppressive factor indoleamine 2,3-dioxygenase (IDO) and primary keratinocytes from a nonautologous source to confer immune protection of xenogeneic cells cultured in a bilayer ESS. The results show that engraftment of IDO expressing skin substitutes on the back of rats significantly improves healing progression over 7 days compared with both nontreated and non-IDO-expressing skin substitutes (p<0.001). Immuno-staining of CD3 and CD31 suggests that IDO-expressing skin substitutes significantly suppress T cell infiltration (p<0.001) and improve neovascularization by four-fold (12.6±1.2 vs. 3.0±1.0 vessel-like structure/high power field), respectively. In conclusion, we found that IDO expression can improve the efficacy of nonautologous ESS for the purpose of wound healing by mitigating T-cell infiltration as well as promoting vascularization of the graft.lld:pubmed
pubmed-article:20955343pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20955343pubmed:languageenglld:pubmed
pubmed-article:20955343pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20955343pubmed:citationSubsetIMlld:pubmed
pubmed-article:20955343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20955343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20955343pubmed:statusMEDLINElld:pubmed
pubmed-article:20955343pubmed:issn1524-475Xlld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:GhaharyAzizAlld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:BoyceStevenSlld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:AllanSarah...lld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:JaliliReza...lld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:ForouzandehFa...lld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:SuppDorothyDlld:pubmed
pubmed-article:20955343pubmed:authorpubmed-author:HartwellRyan...lld:pubmed
pubmed-article:20955343pubmed:copyrightInfo© 2010 by the Wound Healing Society.lld:pubmed
pubmed-article:20955343pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20955343pubmed:volume18lld:pubmed
pubmed-article:20955343pubmed:ownerNLMlld:pubmed
pubmed-article:20955343pubmed:authorsCompleteYlld:pubmed
pubmed-article:20955343pubmed:pagination614-23lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:meshHeadingpubmed-meshheading:20955343...lld:pubmed
pubmed-article:20955343pubmed:articleTitleLocal expression of indoleamine 2,3-dioxygenase suppresses T-cell-mediated rejection of an engineered bilayer skin substitute.lld:pubmed
pubmed-article:20955343pubmed:affiliationBurn and Wound Healing Research Laboratory, Department of Surgery, Immunity and Infection Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.lld:pubmed
pubmed-article:20955343pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20955343pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed